Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844349 | 0.79 | NOTUM (0.41) | SMN1; SMN2HPGDNPC1RAB9ATSHR | |
| SCHEMBL3751447 | 0.79 | MKNK1 (0.39) | SMN1; SMN2HPGDNPC1RAB9ATSHR | |
| SCHEMBL16073029 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2HPGDNPC1RAB9AMAPT | |
| SCHEMBL28702945 | 0.79 | NPC1 (0.31) | SMN1; SMN2HPGDNPC1RAB9ATSHR | |
| SCHEMBL18278129 | 0.77 | KEAP1 (0.47) | SMN1; SMN2NPC1NOTUMKMT2ATP53 | |
| SCHEMBL18291888 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL22897475 | 0.75 | CYP11B2 (0.41) | SMN1; SMN2MAPTNOTUMALDH1A1TDP1 | |
| SCHEMBL28682705 | 0.75 | NOTUM (0.32) | NOTUMALDH1A1 | |
| SCHEMBL22897465 | 0.75 | CYP1A2 (0.47) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL22660841 | 0.75 | KCNH2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20230077362-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-03-16 | — | — | US | disclosed |
| CN-114072000-A | Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113444097-A | Tri-carbazole derivative, organic photoelectric device, and display or lighting device | 浙江华显光电科技有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2021011722-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | disclosed |
| WO-2018106646-A1 | AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | SMN1; SMN2 1774/4885HPGD 1582/4885NPC1 3467/4885 |
| US-20230077362-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | SMN1; SMN2 2662/4885HPGD 1320/4885NPC1 2144/4885 |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | PMP22, MYT1, IKZF3 | SMN1; SMN2 32/4885HPGD 2649/4885NPC1 346/4885 |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | SMN1; SMN2 32/4885HPGD 2649/4885NPC1 346/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | SMN1; SMN2 2523/4885HPGD 1893/4885NPC1 3112/4885 |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | SMN1; SMN2 119/4885HPGD 1990/4885NPC1 1117/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SMN1; SMN2 1774/4885HPGD 1582/4885NPC1 3467/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | SMN1; SMN2 32/4885HPGD 2649/4885NPC1 346/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SMN1; SMN2 1774/4885HPGD 1582/4885NPC1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.